These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Influence of preoperative anti-HLA antibodies on short- and long-term graft survival in recipients with or without rituximab treatment. Ishida H; Furusawa M; Shimizu T; Nozaki T; Tanabe K Transpl Int; 2014 Apr; 27(4):371-82. PubMed ID: 24438437 [TBL] [Abstract][Full Text] [Related]
9. Characteristics of donor-specific anti-HLA antibodies and outcome in renal transplant patients treated with a standardized induction regimen. Zecher D; Bach C; Staudner C; Böger CA; Bergler T; Banas B; Spriewald BM Nephrol Dial Transplant; 2017 Apr; 32(4):730-737. PubMed ID: 28339671 [TBL] [Abstract][Full Text] [Related]
10. De novo donor specific antibodies and patient outcomes in renal transplantation. DeVos JM; Patel SJ; Burns KM; Dilioglou S; Gaber LW; Knight RJ; Gaber AO; Land GA Clin Transpl; 2011; ():351-8. PubMed ID: 22755430 [TBL] [Abstract][Full Text] [Related]
11. Deleterious Impact of Donor-Specific Anti-HLA Antibodies Toward HLA-Cw and HLA-DP in Kidney Transplantation. Bachelet T; Martinez C; Del Bello A; Couzi L; Kejji S; Guidicelli G; Lepreux S; Visentin J; Congy-Jolivet N; Rostaing L; Taupin JL; Kamar N; Merville P Transplantation; 2016 Jan; 100(1):159-66. PubMed ID: 26262501 [TBL] [Abstract][Full Text] [Related]
12. C1q Binding Activity of De Novo Donor-specific HLA Antibodies in Renal Transplant Recipients With and Without Antibody-mediated Rejection. Yell M; Muth BL; Kaufman DB; Djamali A; Ellis TM Transplantation; 2015 Jun; 99(6):1151-5. PubMed ID: 25839705 [TBL] [Abstract][Full Text] [Related]
13. Clinical relevance of pretransplant anti-HLA donor-specific antibodies: does C1q-fixation matter? Crespo M; Torio A; Mas V; Redondo D; Pérez-Sáez MJ; Mir M; Faura A; Guerra R; Montes-Ares O; Checa MD; Pascual J Transpl Immunol; 2013 Dec; 29(1-4):28-33. PubMed ID: 23907088 [TBL] [Abstract][Full Text] [Related]
14. Impact of human leukocyte antigen matching and recipients' panel reactive antibodies on two-year outcome in presensitized renal allograft recipients. Meng HL; Jin XB; Li XT; Wang HW; Lü JJ Chin Med J (Engl); 2009 Feb; 122(4):420-6. PubMed ID: 19302748 [TBL] [Abstract][Full Text] [Related]
15. Low levels of human leukocyte antigen donor-specific antibodies detected by solid phase assay before transplantation are frequently clinically irrelevant. Aubert V; Venetz JP; Pantaleo G; Pascual M Hum Immunol; 2009 Aug; 70(8):580-3. PubMed ID: 19375474 [TBL] [Abstract][Full Text] [Related]
16. Donor specific antibodies before and after kidney transplant: the University of Colorado Experience. Cooper JE; Gralla J; Adebiyi O; Wiseman AC; Chan L Clin Transpl; 2013; ():407-12. PubMed ID: 25095536 [TBL] [Abstract][Full Text] [Related]
17. Clinical significance of post kidney transplant de novo DSA in otherwise stable grafts. Cooper JE; Gralla J; Chan L; Wiseman AC Clin Transpl; 2011; ():359-64. PubMed ID: 22755431 [TBL] [Abstract][Full Text] [Related]